US-HEALTH-VIRUS

In this photo illustration a Gilead logo is displayed on a smartphone next to a screen showing a coronavirus graphic on March 25, 2020 in Arlington, Virginia. - Gilead announced on March 25, 2020 that it has submitted a request to the Food and Drug Administration to rescind the exclusive marketing rights it had secured for remdesivir, an antiviral drug that shows promise in treating Covid-19, the disease caused by the new coronavirus. (Photo by Olivier DOULIERY / AFP) (Photo by OLIVIER DOULIERY/AFP via Getty Images)
In this photo illustration a Gilead logo is displayed on a smartphone next to a screen showing a coronavirus graphic on March 25, 2020 in Arlington, Virginia. - Gilead announced on March 25, 2020 that it has submitted a request to the Food and Drug Administration to rescind the exclusive marketing rights it had secured for remdesivir, an antiviral drug that shows promise in treating Covid-19, the disease caused by the new coronavirus. (Photo by Olivier DOULIERY / AFP) (Photo by OLIVIER DOULIERY/AFP via Getty Images)
US-HEALTH-VIRUS
ACQUISTA UNA LICENZA
Come posso utilizzare questa immagine?
475,00 €
EUR

DETTAGLI

Restrizioni:
Contatta l'ufficio locale per informazioni su qualsiasi tipo di uso commerciale o promozionale. Diritti editoriali illimitati per Regno Unito, Stati Uniti, Irlanda, Italia, Spagna, Canada (escluso Quebec). Diritti editoriali limitati in altri Paesi. Contatta l'ufficio locale.
Attestazione:
OLIVIER DOULIERY / Collaboratore
N. Editorial:
1208237136
Collezione:
AFP
Data di creazione:
25 marzo 2020
Data di upload:
Tipo di licenza:
Info sulla liberatoria:
Senza liberatoria. Ulteriori informazioni
Fonte:
AFP
Codice a barre:
AFP
Nome oggetto:
AFP_1Q67SP
Max. dimensione file:
4000 x 2507 px (33,87 x 21,23 cm) - 300 dpi - 2 MB